4[3]Quan WDY, Skeel RT. Malignant pleural, peritoneal, and pericardial effusions and meningeal in filerates [A]. In: Skeel RT. Handbook of cancer chemotherapy[ C ]. 3rd ed. Boston: Little, Brown and Company,1991.423 - 423.
5Kawata A, Une Y,Hosokawa M, et al. Adjuvant chemcoimmunotherapy for hepatocellular carcinorma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone [J]. Am J Clin Oncol, 1995,18(3) :257-262.
6Uchino J, Une Y, Kawata A, et al. Postoperative chemoimmunotherapy for the treatment of liver cancer [J]. Semin Surg Oncol, 1993,9 (4):332-335.
7Boehm U, Klamp T, Groot M, et al. Cellular response to interferongamma[J]. Ann Rev Immunol. 1997.15(1):749-795.
8Wadler S.The role of interferons in the treatment of solid tumors[J].Cancer, 1991,70[4 Suppl] :949-958.
9Mofikawa K. Recombinant interferon-alpha,-beta,and -gamma enhance the proliferative response of human B cells[J]. J Immunol, 1987, 139(3) :761.
10Dinney CP. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration [J]. Cancer Res, 1998,58 (4) : 808.
